Clinical Trials Browser

Phase 1/2 × spartalizumab × 30 days × Clear all

NCT07353645 2026-04-15

KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06425926 2026-03-27

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Phase 1/2 Recruiting

Melanoma